Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530631 · ClinicalTrials.gov registry record · Phase 4
Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03530631 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 4 participants.
The verdict
NCT03530631, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this balanced-placebo design study is to pilot a larger study to further explore the current evidence that stimulant medications are not cognitive enhancers, despite this rampant belief in young adults. While the lack of cognitive enhancement from stimulant medication has been documented in prior research, this study is the first to utilize neuroimaging technology to examine brain regions activated during neurocognitive tasks when participants believe they have been administered stimulant medication or placebo.
Interventions
- DRUG Placebo
- DRUG Adderall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-11-10 |
| Est. Completion | 2018-12-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03530631
The ClinicalTrials.gov registry entry for NCT03530631 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03530631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03530631 about?
NCT03530631 is a clinical study titled "Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance". The purpose of this balanced-placebo design study is to pilot a larger study to further explore the current evidence that stimulant medications are not cognitive enhancers, despite this rampant belief in young adults. While the lack of cognitive enhancement from stimulant medication has been documen...
What is the current status of trial NCT03530631?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2018-11-10. Estimated completion is 2018-12-18.
What interventions are being tested in trial NCT03530631?
The interventions under investigation include: Placebo (DRUG), Adderall (DRUG).
Who is sponsoring clinical trial NCT03530631?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.